实验室作为科学的摇篮，是科研人员解决生物医用材料关键科学问题、突破核心技术、提升成果转化力必不可少的研究基地，而科学仪器又 是科研人员在实验室进行科学研究必不可少的工具。为此，仪器信息网特汇总分析了生物育种领域实验室的仪器设备明细，并推出生物育种 领域实验室高频配置仪器清单，供读者参考。 生物育种实验室主要仪器配置清单 （ 其 中 部 分 仪 器 来 自 上 述 实 验 室 公 共 仪 器 平 台 以 及 近 一 年 采购 ） 摘要 ： 为此，仪器信息网特汇总分析了生物育种领域实验室的仪器设备明细，并推出生物育种领域实验室高频配置仪器清单，供读者参考。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 种子是农业的"芯片"， 生物育种是 打造种业"芯片"的关键之 一 。根据我国"十 五 五" ， 规划明确 "发展生物育种、生物制药" 。 我国 确立了生物育种优先发展战略，以加快实施生物育种重大科技计划。在当前形势下，全方位筑牢粮食安全的根基、强化农业科技和装备的支 撑作用、加速推进生物育种的原始创新以及产业化应用，是打赢种业翻身仗的关键举措。 ...

Core Insights - The life sciences instrument sector is experiencing significant capital inflow and technological innovation in 2025, with a notable trend towards domestic substitution [1][2] - The financing activity in the first half of 2025 has surpassed that of the same period in 2024, with a total of approximately 1.5 billion yuan raised across 13 financing events [2] Financing Overview - In the first half of 2025, 13 financing events were completed, totaling around 1.5 billion yuan, with a balanced distribution across various financing rounds: 4 in A round, 4 in B round, 3 in C round, and 2 in angel round [2] - Key financing events include: - Kunpeng Gene: over 100 million yuan in B round [2] - Yinsais: several hundred million yuan in C round [2] - Zhenmai Bio: 280 million yuan in C+ round, the highest amount in the first half [3][2] Sector Analysis - Sequencing and synthetic biology are leading the investment landscape, with sequencing-related companies accounting for over 30% of the financing events [3] - The market for sequencing instruments is expected to maintain a compound annual growth rate of over 20% due to increasing demand for precision medicine and single-cell sequencing [3] Synthetic Biology Financing - Synthetic biology has emerged as a hot investment area since 2024, continuing into 2025, with significant financing amounts [4] - Companies like Yinsais and Lingzhi Technology are focusing on nucleic acid synthesis and DNA synthesis, respectively, aligning with global trends in mRNA technology [4] AI and Advanced Instrumentation - Companies are integrating AI with high-end instrumentation, exemplified by Tianlu Technology's intelligent experimental design tools and Chaowei Jing's multi-photon microscope [5] - This trend indicates a shift towards interdisciplinary innovation, enhancing the competitiveness of domestic instruments [5] Domestic Instrumentation Landscape - Lid Health's substantial angel round financing has drawn attention, positioning the company as a comprehensive supplier of high-end life science instruments [6] - The company aims to consolidate the market by acquiring smaller players, drawing parallels with international leaders like Thermo Fisher [6] Policy and Market Dynamics - The rapid development of domestic life science instruments is driven by supportive policies and growing market demand, particularly in biomedicine and CGT sectors [7] - Despite active financing, domestic manufacturers face challenges such as reliance on imported core components and the need for brand recognition [7] Future Outlook - The life sciences instrument sector is expected to see a shift from broad investment strategies to a more focused approach, favoring companies with high technological barriers and significant domestic substitution potential [8] - The industry is anticipated to produce several "hidden champions" in niche areas within the next 3-5 years, moving towards the high end of the global value chain [8]